Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen mRNA Vaccine in Advanced Solid Tumors
NCT06195384Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- May 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Number of Patients with Dose Limiting Toxicity at 6 months. Started May 2024; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06195384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195384.